ARLIDIN: A CLINICAL EVALUATION OF A PERIPHERAL VASODILATOR WITH SELECTIVE ACTION ON MUSCLE VESSELS

Publisher Website
Google Scholar
Abstract
Arlidin, a new vasodilator chemically related to epinephrine was given to 220 patients with intermittent claudication due to organic arterial disease. In contrast to most commonly-used vasodilators which act upon vessels of the skin, Arlidin increases blood flow to the calf with its large muscle mass. Two thirds of these patients, whose walking tolerance has been stabilized showed significant improvement in walking in 1-3 weeks of oral use of 6 mg three times a day. Plethysmographic measurement showed an increase of blood flow in the calf after injection of a single dose of 6 mg of Arlidin into the femoral artery. This was 3-4 times the resting blood flow for the area, approximated the maximal blood flow possible and persisted for 1 to 2 hours.
Keywords

This publication has 2 references indexed in Scilit: